7-117642566-G-C
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PM5PP3_ModeratePP5
The ENST00000003084.11(CFTR):āc.3846G>Cā(p.Trp1282Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,613,376 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. W1282G) has been classified as Pathogenic.
Frequency
Consequence
ENST00000003084.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3846G>C | p.Trp1282Cys | missense_variant | 23/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.3846G>C | p.Trp1282Cys | missense_variant | 23/27 | 1 | NM_000492.4 | ENSP00000003084 | P2 | |
ENST00000456270.1 | n.65+4785C>G | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152130Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250892Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135602
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461246Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726928
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152130Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74304
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:2Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 05, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 19, 2021 | The p.W1282C variant (also known as c.3846G>C), located in coding exon 23 of the CFTR gene, results from a G to C substitution at nucleotide position 3846. The tryptophan at codon 1282 is replaced by cysteine, an amino acid with highly dissimilar properties. Limited functional studies demonstrated lower levels of mature protein and reduced chloride conductance (Xue X et al. Hum. Mol. Genet., 2017 08;26:3116-3129). This variant disrupts a buried residue lying inside a pocket lined with aromatic side chains. Another alteration at this amino acid position, p.W1282G, was reported in an individual with elevated sweat chloride, pancreatic insufficiency, Pseudomonas aeruginosa colonization, and p.F508del (Faucz FR et al. Clin. Genet., 2007 Sep;72:218-23). Based on data from gnomAD, the C allele has an overall frequency of <0.01% (1/250892) total alleles studied. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 09, 2022 | This sequence change replaces tryptophan, which is neutral and slightly polar, with cysteine, which is neutral and slightly polar, at codon 1282 of the CFTR protein (p.Trp1282Cys). This variant is present in population databases (rs77010898, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with CFTR-related conditions. ClinVar contains an entry for this variant (Variation ID: 598323). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). Experimental studies have shown that this missense change affects CFTR function (PMID: 28575328, 31776420). This variant disrupts the p.Trp1282 amino acid residue in CFTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 29504914, 30548586; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 26, 2024 | Variant summary: CFTR c.3846G>C (p.Trp1282Cys) results in a non-conservative amino acid change located in the second ATP-binding domain (IPR003439) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.9e-06 in 1,606,386 control chromosomes (gnomAD v4). The variant, p.Trp1282Cys, has been reported in the literature in at least two individuals affected with Cystic Fibrosis, who caried a second pathogenic CFTR variant (Gunnett_2023). These data indicate that the variant may be associated with disease. Publications also reported experimental evidence evaluating an impact on protein function, and demonstrated reduced CFTR function (Xue_2017, Phuan_2019). In addition, different missense variants affecting the same residue (W1282R/G) have been reported in affected individuals, and been classified as Pathogenic in ClinVar, indicating a functional importance for this amino acid. ClinVar contains an entry for this variant (Variation ID: 598323). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
not provided Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 15, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Feb 23, 2022 | PP3, PM2, PM3_supporting, PS3 - |
CFTR-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 17, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at